Justin Skoble - Caribou Biosciences VP Operations

Caribou Biosciences Management Efficiency

The company has return on total asset (ROA) of (0.2514) % which means that it has lost $0.2514 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.436) %, meaning that it created substantial loss on money invested by shareholders. Caribou Biosciences' management efficiency ratios could be used to measure how well Caribou Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.25 in 2024. Return On Capital Employed is likely to drop to -0.3 in 2024. Total Current Liabilities is likely to drop to about 23 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 296.2 M in 2024

Similar Executives

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. The company was incorporated in 2011 and is headquartered in Berkeley, California. Caribou Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Caribou Biosciences (CRBU) is traded on NASDAQ Exchange in USA. It is located in 2929 7th Street, Berkeley, CA, United States, 94710 and employs 158 people. Caribou Biosciences is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Caribou Biosciences Leadership Team

Caribou Stock Performance Indicators

Additional Tools for Caribou Stock Analysis